In this multi-billion dollar market, this is encouraging news for Cannabis Science shareholders as small dosages of cannabis provided rest from chronic even, neuropathic pain, which might be caused by physical injuries or by anti-viral drugs used to treat HIV/AIDS. Cannabis Science President and CEO Dr. Robert Melamede, PhD. As Dr. Ware said at the start of the CMAJ content, cannabis sativa has been used to take care of pain since the third millennium BC, so it is all the more outrageous that it has taken such a long time for such a study to be done, and it could only be used by patients who didn’t respond to other things. Why do they need to suffer so much to verify what virtually all medical marijuana users know?’ Related StoriesDigiPath Labs, Romer Labs to validate kit-based assays for food-borne pathogen, mycotoxin examining for cannabisBRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical SchoolNew research shows cannabinoid cannabidiol can help heal bone fracturesMcGill’s research is the initial double-blind, placebo-controlled trial carried out with outpatients who were allowed to smoke marijuana within their own homes.In the meantime, for those who qualify, COBRA is normally very costly without the subsidy . This article is republished with kind permission from our friends at The Kaiser Family Foundation. You will see the entire Kaiser Daily Health Policy Report, search the archives, or join email delivery of in-depth coverage of wellness policy developments, debates and discussions. The Daily Health Plan Report is released for Kaisernetwork.org, a free of charge program of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Business and Kaiser Family Foundation. All rights reserved.
BPC praises FDA draft help with non-proprietary naming of biological products Biosimilars aren’t generics and the Biologics Prescribers Collaborative applauds the U.S.